Thursday, 20 Sep 2018

Biologic/Novel Rx

Datesort ascending Type Title Save
20 Sep 2018 News Unproven But Profitable Stem Cell Clinics
11 Sep 2018 News Out of Pocket Costs for Biosimilars - No Savings So Far
11 Sep 2018 News Cutting Oral JAK 1/2 Inhibitor Dose an Option in RA
04 Sep 2018 News Tocilizumab Equals other Biologics in Cardiovascular Risk
30 Aug 2018 Slide of the day Still's Disease Survey Results: July 2018
30 Aug 2018 News Treatment Preferences in Still’s Disease
30 Aug 2018 Social Innate immune responses induced by GM-CSF induction of NLRP3 expression and IL-1β production by neutrophils can be blocked by tofacitinib. Could tofacitinib be effective in Still's disease and other autoinflammatory disorders? https://t.co/1eynwIbl6d
28 Aug 2018 News Questions Remain about Shingrix Safety in Rheumatic Disease
13 Aug 2018 News Success of Stopping Depends on the Biologic
06 Aug 2018 Social Psoriasis biologic pipeline continues to grow. In development are IL-23 inhibitors (risankizumab, mirikizumab) & the IL-17 A/F inhbitor (bimekizumab). Tildrakizumab and certolizumab were approved for Psoriasis earlier in 2018. https://t.co/QFbdtO1Lua
04 Aug 2018 Social Switching to biosimilars (and generics) saved the UK National Health Service NHS England saved £324 million in 2017/2018. https://t.co/WxpWYAt3bh
02 Aug 2018 Social Pfizers announces EU approval for tofacitinib 10 mg bid for use in adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to DMARD or biologic agents https://t.co/Cw9JFozphJ
01 Aug 2018 Social Positive Results from Phase III study of RHB-104 in Crohn’s Disease; RHB-104 is a combo antimycobacterial-antibiotic with antiinflammatory properties (given w/ hypothesis that CD caused by a mycobacterium avium paratuberculosis https://t.co/w78xCKkAlG
01 Aug 2018 News IL-1 Suppression May Improve Dilated Cardiomyopathy
31 Jul 2018 Social EMA's CHMP has recommended approval of the IL-23 inhibitor tildrakizumab (Ilumetri, Almirall) for adults with moderate - severe plaque psoriasis. (Based on reSURFACE1 and reSURFACE2 RCTs w/ >80% PASI 75 responses. https://t.co/Qm0qIgAJ2G
20 Jul 2018 Social RT @AngusWorthing: FDA releases #biosimilars action plan. @ACRheum through AMA has pushed FDA to finalize interchangeability pathway. Fing…
14 Jul 2018 Social RheumNow coverage of Biologic use and switching from the BSRBR database https://t.co/j3rAiFjjWh https://t.co/jIFSBEnvzc
12 Jul 2018 Social RT @ByJonGardner: Some interesting insight on why US biosimilar uptake has been so anaemic from a Leerink note. Main reasons: PBMS lose mon…
12 Jul 2018 News Defining Refractory RA by Biologic Use
11 Jul 2018 News IL-23 Inhibitor Fails in Ankylosing Spondylitis